Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis.

Loading...
Thumbnail Image

Embargo End Date

Authors

Lambros, MB
Seed, G
Sumanasuriya, S
Gil, V
Crespo, M
Fontes, M
Chandler, R
Mehra, N
Fowler, G
Ebbs, B
Flohr, P
Miranda, S
Yuan, W
Mackay, A
Ferreira, A
Pereira, R
Bertan, C
Figueiredo, I
Riisnaes, R
Rodrigues, DN
Sharp, A
Goodall, J
Boysen, G
Carreira, S
Bianchini, D
Rescigno, P
Zafeiriou, Z
Hunt, J
Moloney, D
Hamilton, L
Neves, RP
Swennenhuis, J
Andree, K
Stoecklein, NH
Terstappen, LWMM
de Bono, JS

Document Type

Journal Article

Date

2018-11-15

Date Accepted

2018-07-18

Abstract

Purpose: Circulating tumor cells (CTCs) have clinical relevance, but their study has been limited by their low frequency.Experimental Design: We evaluated liquid biopsies by apheresis to increase CTC yield from patients suffering from metastatic prostate cancer, allow precise gene copy-number calls, and study disease heterogeneity.Results: Apheresis was well tolerated and allowed the separation of large numbers of CTCs; the average CTC yield from 7.5 mL of peripheral blood was 167 CTCs, whereas the average CTC yield per apheresis (mean volume: 59.5 mL) was 12,546 CTCs. Purified single CTCs could be isolated from apheresis product by FACS sorting; copy-number aberration (CNA) profiles of 185 single CTCs from 14 patients revealed the genomic landscape of lethal prostate cancer and identified complex intrapatient, intercell, genomic heterogeneity missed on bulk biopsy analyses.Conclusions: Apheresis facilitated the capture of large numbers of CTCs noninvasively with minimal morbidity and allowed the deconvolution of intrapatient heterogeneity and clonal evolution. Clin Cancer Res; 24(22); 5635-44. ©2018 AACR.

Citation

Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 24 (22), pp. 5635 - 5644

Source Title

Publisher

AMER ASSOC CANCER RESEARCH

ISSN

1078-0432

eISSN

1557-3265

Research Team

Cancer Biomarkers
Prostate Cancer Targeted Therapy Group
Translational Therapeutics
Glioma Team

Notes